Meeting
2023 ASCO Annual Meeting
Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).
Authors
Emily Gustava Greengard
University of Minnesota, Eden Prairie, MN
Emily Gustava Greengard , Melissa Bear , Bradley DeNardo , Noah Federman , Julie Krystal , Giselle Linda Saulnier Sholler , Yanhong Zhou , Holly Knoderer , Sarah C Nabinger , Lindsey M. Hoffman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT04238819
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS10068)
DOI
10.1200/JCO.2023.41.16_suppl.TPS10068
Abstract #
TPS10068
Poster Bd #
373a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.
First Author: Cristina Larrosa
Poster
2023 ASCO Annual Meeting
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).
First Author: Álvaro Lassaletta
Poster
2023 ASCO Annual Meeting
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.
First Author: Gertjan VAN HAL
Poster
2022 ASCO Annual Meeting
Progression-free survival and patterns of response in patients with high-risk neuroblastoma (HR-NB) treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSFS) chemoimmunotherapy.
First Author: Benjamin Lerman